Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-Segment Elevation Myocardial Infarction: vascular healing outcomes from the MAGSTEMI trial.

The MAGSTEMI trial showed larger angiographic lumen loss and restenosis with Magnesium-based bioresorbable scaffold (MgBRS) than with sirolimus-eluting stent (SES). Ninety-five patients (MgBRS=48 and SES=47) underwent to OCT imaging at 1 year. Devices with indiscernible struts were observed in 33.3% vs. 0% (p<0.001); struts integrated into the vessel wall in 22.9% vs. 63.8% (p<0.001); protruding struts in 37.5% vs. 31.9% (p=0.568), and; protruding and malapposed struts in 6.3% vs. 4.3% (p=0.663), respectively. Minimal lumen area (3.92+/-2.02 vs. 6.31+/-1.71mm; p<0.001) and expansion index (0.58+/-0.16 vs. 0.86+/-0.19; p<0.001) were smaller with MgBRS. The main cause of MgBRS restenosis was scaffold collapse (50%). Further generations of MgBRS should prolong the radial force.